AbbVie partners with Gilgamesh Pharma to develop next-gen psychedelic drugs for psychiatric disorders, paying $65M upfront and up to $1.95B in milestones.
AbbVie (ABBV) partners with Gilgamesh Pharmaceuticals to explore next-gen psychedelic drugs for psychiatric disorders. The collaboration aims to develop neuroplastogens with reduced side effects. AbbVie will lead development and commercialization, paying Gilgamesh an upfront $65M upon exercising the option, with potential milestone payments up to $1.95B and tiered royalties on net sales.
May 13, 2024
3 Articles